UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM 8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
August
4, 2015
USANA HEALTH
SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Utah
(State
or other jurisdiction of incorporation)
001-35024
|
|
87-0500306
|
(Commission File No.)
|
|
(IRS Employer Identification
|
|
|
Number)
|
3838 West Parkway Boulevard Salt Lake City, Utah 84120
|
(Address
of principal executive offices, Zip
Code)
|
Registrant’s
telephone number, including area code: (801)
954-7100
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02 Results of Operations and Financial
Condition.
On August 4, 2015, USANA Health Sciences, Inc. issued a press release
announcing its financial results for the second quarter and six months
ended July 4, 2015. The release also announced that the Company will
post a document titled “Management Commentary, Results and Outlook” on
the Company’s website and that executives of the company would hold a
conference call with investors, to be broadcast over the World Wide Web
and by telephone and provided access information, date and time for the
conference call. The Company noted that the call will consist of brief
remarks by the Company’s management team, before moving directly into
questions and answers. A copy of the press release, and the Management
Commentary, Results and Outlook, are furnished herewith as Exhibits to
this Current Report on Form 8-K and are incorporated herein by
reference. These documents will be posted on the Company’s corporate
website, www.usanahealthsciences.com.
The information in this Current Report is being furnished and shall not
be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. The information in this Current Report
shall not be incorporated by reference into any registration statement
or other document pursuant to the Securities Act of 1933, as amended.
The furnishing of the information in this Current Report is not intended
to, and does not, constitute a representation that such furnishing is
required by Regulation FD or that the information this Current Report
contains is material investor information that is not otherwise publicly
available.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
(c)
On August 4, 2015, the Company announced that the Board of Directors has
approved a Co-Chief Executive Officer leadership structure for the
Company and that David A. Wentz and Kevin G. Guest will serve as
Co-Chief Executive Officers of the Company and report directly to the
Board of Directors. Mr. Wentz will oversee USANA’s global operations
while Mr. Guest will lead USANA’s worldwide field development and sales
efforts.
Mr. Wentz has served as Chief Executive Officer of the Company since
July 2008. For the last 12 months, Mr. Wentz had reduced his time in
the office to spend more time with his family and to work on several
strategic initiatives. He returned to the Company on a full-time basis
on August 3, 2015. As Co-Chief Executive Officer, Mr. Wentz will
receive an annual salary of $618,000, continue to be eligible to
participate in the Company’s Executive Bonus Plan, and be eligible to
receive equity grants under the Company’s 2015 Equity Incentive Award
Plan. Mr. Wentz will also be eligible to participate in the Company’s
401K plan and to receive medical and other benefits coverage, which is
generally available to the Company’s other employees.
Mr. Guest has served as President of USANA world-wide since August
2014. Prior to serving as President, Mr. Guest served as President of
the Americas, Europe and South Pacific from May 2011 to October 2012,
and Chief Marketing Officer from July 2008 to May 2011. As Co-Chief
Executive Officer, Mr. Guest will receive an annual salary of $618,000,
continue to be eligible to participate in the Company’s Executive Bonus
Plan, and be eligible to receive equity grants under the Company’s 2015
Equity Incentive Award Plan. He will also be eligible to participate in
the Company’s 401K plan and to receive medical and other benefits
coverage, which is generally available to the Company’s other employees.
The Company also announced that on August 4, 2015, Chief Financial
Officer, Paul A. Jones, was appointed Chief Leadership Development
Officer of the Company where he will oversee the key role of the
Company’s executive development and succession program. Mr. Jones will
assume this new role immediately and continue his CFO responsibilities
while the Company facilitates its search for a new Chief Financial
Officer.
The press release issued by the Company on August 4, 2015 announcing
these events is attached hereto as Exhibit 99.3 and incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued by USANA Health Sciences, Inc.
dated August 4, 2015 (furnished herewith).
Exhibit
99.2 Management Commentary, Results and Outlook provided by USANA
Health Sciences, Inc. dated August 4, 2015 (furnished herewith).
Exhibit
99.3 Press release issued by USANA Health Sciences, Inc. dated
August 4, 2015 (furnished herewith).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
USANA HEALTH SCIENCES, INC.
|
|
|
|
|
|
|
|
|
By: /s/ Paul A. Jones
|
|
|
|
|
|
Paul A. Jones, Chief Financial Officer
|
|
|
|
Date:
|
August 4, 2015
|
|
Exhibit 99.1
USANA
Health Sciences Reports Record Net Sales of $233.2 Million; 41% Increase
in EPS for Second Quarter 2015
-
Second
quarter net sales increased 23.9% to $233.2 million
-
Second
quarter EPS increased 41.2% to $1.92
-
Number
of active Associates increased 40.3% to 397,000
-
Company
increases outlook for 2015
SALT LAKE CITY--(BUSINESS WIRE)--August 4, 2015--USANA Health Sciences,
Inc. (NYSE: USNA) today announced record financial results for its
fiscal second quarter ended July 4, 2015. The Company also increased its
financial outlook for 2015.
Financial Performance
For the second quarter of 2015, net sales increased to $233.2 million,
up 23.9% compared with $188.3 million in the prior-year period. The
increase in net sales was driven by 40.3% growth in the number of active
Associates and 15.2% growth in the number of Preferred Customers. Also
included in net sales for the quarter is $5 million in revenue that was
deferred during the previous quarter in connection with price increases
in China. Fluctuations in currency exchange rates negatively impacted
net sales by $9.7 million due to the strengthening of the U.S. dollar.
Net earnings for the second quarter increased by 31.7% to $25.4 million,
compared with $19.3 million during the prior-year period. The increase
in net earnings was driven by higher net sales, improved gross margins
and lower relative selling, general and administrative expense, which
were partially offset by higher relative Associate Incentives expense.
Earnings per diluted share for the second quarter increased 41.2% to
$1.92, compared with $1.36 in the prior year period. The increase in
earnings per share was attributable to higher net earnings and a lower
number of diluted shares outstanding due to the Company’s share
repurchases during 2014. Weighted average diluted shares outstanding
were 13.2 million as of the end of the second quarter of 2015, compared
with 14.2 million in the prior-year period. During the second quarter of
2015, the Company did not repurchase any shares of common stock.
The Company ended the second quarter with $150.9 million in cash and
cash equivalents, zero debt and $61.2 million remaining under the
current share repurchase authorization.
“USANA generated exceptional results during the second quarter, which
again included double-digit growth in sales, earnings and customers,”
said Kevin Guest, USANA’s President. “Our better-than-expected results
reflect the strong momentum we are seeing in our business, which is
largely being driven by our strategies for customer growth.”
Regional Results
Net sales in the Asia Pacific region increased by 35.4% to $168.7
million, compared with $124.6 million for the second quarter of the
prior year. Sales grew 51.6% in the Greater China region, 7.8% in the
Southeast Asia Pacific region and 32.4% in the North Asia region. Sales
growth in Greater China was driven by strong customer growth in Mainland
China, while growth in Southeast Asia Pacific resulted from customer
growth within each market in the region. Finally, sales growth in North
Asia was driven by double-digit customer growth in South Korea.
The number of active Associates in the Asia Pacific region increased by
53.2% year-over-year, and increased 6.2% sequentially. Net sales in the
Asia Pacific region were negatively impacted by $5.1 million due to the
strengthening of the U.S. dollar.
Net sales in the Americas/Europe region increased modestly to $64.5
million and were negatively impacted by $4.6 million due to the
strengthening of the U.S. dollar. Canada, Mexico and Colombia all
generated double-digit customer growth in the second quarter, compared
with the prior year period.
“Although currency remains a headwind, our business continues to
generate solid worldwide growth,” continued Guest. “While Mainland China
continues to lead the way, it is noteworthy that USANA generated both
sales and customer growth in nearly every market around the world, which
reflects the demand for our best-in-class products and business
opportunity. During the quarter, we held our annual Asia Pacific
convention in Singapore, where thousands of our Associates celebrated
their success and received additional training. Later this month, we
will hold our annual International Convention in Salt Lake City, where
we also expect record attendance and another amazing event.”
Outlook
The Company provided the following updated consolidated net sales and
earnings per share outlook for 2015:
-
Consolidated net sales between $900 million and $920 million, versus
the previous outlook of between $870 million and $890 million
-
Earnings per share between $6.90 and $7.20, versus the previous
outlook of between $6.45 and $6.75
Chief Financial Officer Paul Jones said, “During the quarter, our team
capitalized on the leverage opportunity created by higher sales. As we
anticipated, our Associate Incentives expense returned to our customary
range following the completion of our promotional activities during the
prior two quarters. The relative improvement in both gross margins and
SG&A for the quarter also enhanced this leverage. In light of our better
than expected results during the first half of 2015, and the momentum we
continue to see in our business, we are increasing our outlook for 2015
and look forward to delivering another year of record results for USANA
and its stakeholders.”
Conference Call
The Company has posted the “Management Commentary, Results and Outlook”
document on the Company’s website (www.usanahealthsciences.com)
under the “Investor Relations” section of the site. USANA will hold a
conference call and webcast to discuss today’s announcement with
investors on Wednesday, August 5, 2015 at 11:00 a.m. Eastern Time. Investors
may listen to the call by accessing USANA’s website at http://www.usanahealthsciences.com.
The call will consist of brief opening remarks by the Company’s
management team, before moving directly into questions and answers.
About USANA
USANA develops and manufactures high-quality nutritional supplements,
healthy foods and personal care products that are sold directly to
Associates and Preferred Customers throughout the United States, Canada,
Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea,
Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the
United Kingdom, Thailand, France, Belgium and Colombia. More information
on USANA can be found at http://www.usanahealthsciences.com.
Safe Harbor
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Our actual results could differ materially from
those projected in these forward-looking statements, which involve a
number of risks and uncertainties, including global economic conditions
generally, reliance upon our network of independent Associates, the
governmental regulation of our products, manufacturing and marketing
risks, adverse publicity risks, and risks associated with our
international expansion. The contents of this release should be
considered in conjunction with the risk factors, warnings and cautionary
statements that are contained in our most recent filings with the
Securities and Exchange Commission.
USANA Health Sciences, Inc.
|
Consolidated Statements of Earnings
|
(In thousands, except per share data)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
Six Months Ended
|
|
|
|
|
|
|
28-Jun-14
|
|
4-Jul-15
|
|
|
28-Jun-14
|
|
4-Jul-15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
$
|
188,256
|
|
$
|
233,244
|
|
|
|
$
|
370,657
|
|
$
|
452,622
|
Cost of sales
|
|
|
|
34,865
|
|
|
40,089
|
|
|
|
|
68,693
|
|
|
78,453
|
|
|
Gross profit
|
|
|
|
153,391
|
|
|
193,155
|
|
|
|
|
301,964
|
|
|
374,169
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
Associate incentives
|
|
|
|
81,098
|
|
|
101,877
|
|
|
|
|
159,972
|
|
|
203,230
|
|
Selling, general and administrative
|
|
|
|
43,206
|
|
|
52,505
|
|
|
|
|
87,783
|
|
|
102,380
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
|
|
29,087
|
|
|
38,773
|
|
|
|
|
54,209
|
|
|
68,559
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
|
297
|
|
|
(86
|
)
|
|
|
|
422
|
|
|
82
|
|
|
Earnings before income taxes
|
|
|
|
29,384
|
|
|
38,687
|
|
|
|
|
54,631
|
|
|
68,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes
|
|
|
|
10,083
|
|
|
13,271
|
|
|
|
|
18,793
|
|
|
23,545
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET EARNINGS
|
|
|
$
|
19,301
|
|
$
|
25,416
|
|
|
|
$
|
35,838
|
|
$
|
45,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share - diluted
|
|
|
$
|
1.36
|
|
$
|
1.92
|
|
|
|
$
|
2.50
|
|
$
|
3.43
|
Weighted average shares outstanding - diluted
|
|
|
|
14,235
|
|
|
13,225
|
|
|
|
|
14,315
|
|
|
13,155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
USANA Health Sciences, Inc.
|
Consolidated Balance Sheets
|
(In thousands)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
As of
|
|
|
|
|
|
ASSETS
|
|
|
3-Jan-15
|
|
4-Jul-15
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
$
|
111,126
|
|
$
|
150,929
|
|
|
|
|
|
|
Inventories
|
|
|
|
45,248
|
|
|
54,022
|
|
|
|
|
|
|
Prepaid expenses and other current assets
|
|
|
|
34,553
|
|
|
39,864
|
|
|
|
|
|
|
Total current assets
|
|
|
|
190,927
|
|
|
244,815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
|
71,164
|
|
|
73,939
|
|
|
|
|
|
|
Goodwill
|
|
|
|
17,941
|
|
|
17,948
|
|
|
|
|
|
|
Intangible assets, net
|
|
|
|
40,952
|
|
|
40,763
|
|
|
|
|
|
|
Deferred income taxes
|
|
|
|
5,933
|
|
|
5,998
|
|
|
|
|
|
|
Other assets
|
|
|
|
23,667
|
|
|
25,047
|
|
|
|
|
|
|
Total assets
|
|
|
$
|
350,584
|
|
$
|
408,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
$
|
7,779
|
|
$
|
9,038
|
|
|
|
|
|
|
Other current liabilities
|
|
|
|
100,926
|
|
|
103,818
|
|
|
|
|
|
|
Total current liabilities
|
|
|
|
108,705
|
|
|
112,856
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities
|
|
|
|
1,114
|
|
|
1,062
|
|
|
|
|
|
|
Deferred income taxes
|
|
|
|
10,601
|
|
|
10,068
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity
|
|
|
|
230,164
|
|
|
284,524
|
|
|
|
|
|
|
Total liabilities and stockholders' equity
|
|
|
$
|
350,584
|
|
$
|
408,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
USANA Health Sciences, Inc.
|
Sales by Region
|
(Unaudited)
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
28-Jun-14
|
|
|
4-Jul-15
|
Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Greater China
|
|
|
|
74,091
|
|
39.4
|
%
|
|
|
|
112,333
|
|
48.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Southeast Asia Pacific
|
|
|
|
42,689
|
|
22.7
|
%
|
|
|
|
46,033
|
|
19.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
North Asia
|
|
|
|
7,815
|
|
4.1
|
%
|
|
|
|
10,346
|
|
4.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific Total
|
|
|
|
124,595
|
|
66.2
|
%
|
|
|
|
168,712
|
|
72.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Americas and Europe
|
|
|
$
|
63,661
|
|
33.8
|
%
|
|
|
$
|
64,532
|
|
27.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
$
|
188,256
|
|
100.0
|
%
|
|
|
$
|
233,244
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Associates by Region (1)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
28-Jun-14
|
|
|
4-Jul-15
|
Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Greater China
|
|
|
|
125,000
|
|
44.1
|
%
|
|
|
|
216,000
|
|
54.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Southeast Asia Pacific
|
|
|
|
67,000
|
|
23.7
|
%
|
|
|
|
79,000
|
|
19.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
North Asia
|
|
|
|
9,000
|
|
3.2
|
%
|
|
|
|
13,000
|
|
3.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific Total
|
|
|
|
201,000
|
|
71.0
|
%
|
|
|
|
308,000
|
|
77.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Americas and Europe
|
|
|
|
82,000
|
|
29.0
|
%
|
|
|
|
89,000
|
|
22.4
|
%
|
Total
|
|
|
|
283,000
|
|
100.0
|
%
|
|
|
|
397,000
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Associates are independent distributors of our products who also
purchase our products for their personal use. We only count as
active those Associates who have purchased from us any time during
the most recent three-month period, either for personal use or for
resale.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Preferred Customers by Region (2)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
28-Jun-14
|
|
|
4-Jul-15
|
Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Greater China
|
|
|
|
3,000
|
|
3.8
|
%
|
|
|
|
4,000
|
|
4.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Southeast Asia Pacific
|
|
|
|
11,000
|
|
13.9
|
%
|
|
|
|
12,000
|
|
13.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
North Asia
|
|
|
|
5,000
|
|
6.4
|
%
|
|
|
|
9,000
|
|
9.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific Total
|
|
|
|
19,000
|
|
24.1
|
%
|
|
|
|
25,000
|
|
27.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Americas and Europe
|
|
|
|
60,000
|
|
75.9
|
%
|
|
|
|
66,000
|
|
72.5
|
%
|
Total
|
|
|
|
79,000
|
|
100.0
|
%
|
|
|
|
91,000
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Preferred Customers purchase our products strictly for their
personal use and are not permitted to resell or to distribute the
products. We only count as active those Preferred Customers who have
purchased from us any time during the most recent three-month period.
|
CONTACT:
USANA Health Sciences, Inc.
Investors contact:
Patrique
Richards, 801-954-7961
Investor Relations
investor.relations@us.usana.com
or
Media
contact:
Dan Macuga, 801-954-7280
Public Relations
Exhibit 99.2
USANA Health Sciences, Inc.
Q2 2015 Management Commentary,
Results and Outlook
-
Second quarter net sales increased 23.9% to $233.2
-
Second quarter EPS increased by 41.2% to $1.92
-
Number of active Associates increased by 40.3%
-
Company increases outlook for 2015
|
August 4, 2015
Overview
The second quarter was another record quarter for USANA. Net sales
increased by 23.9% to $233.2 million on a year-over-year basis. Sales
growth was driven by overall Associate growth of 40.3% and Preferred
Customer growth of 15.2%. Associate growth was primarily generated by
our Asia Pacific region where the number of active Associates increased
53.2% year-over-year. Preferred Customers increased in each region
around the world. While our Greater China region continued to lead the
way this quarter, every region generated sales and customer growth.
Also included in net sales for the quarter is $5 million in revenue that
was deferred during the previous quarter in connection with buying ahead
of price increases in China. Unfavorable changes in foreign currency
exchange rates had the affect of reducing net sales by $9.7 million on a
comparative basis. On a constant currency basis, our net sales would
have increased by 29.0% during the current year quarter.
Our better than anticipated sales and customer growth this quarter was
the result of strong momentum in our world-wide business, led by Greater
China, which reflects the demand for USANA’s best-in-class products and
business opportunity. Our current growth strategies, which are centered
on motivating our sales force with market-specific incentives,
increasing our branding recognition and advancing our personalization
initiative, are helping to drive this momentum. In particular, the
market-specific incentives that we have offered over the past few
quarters have created excitement and momentum in our business. These
incentives have been a key factor in accelerating our customer growth in
nearly all of our markets. Additionally, our strategy to increase our
brand recognition, which includes our relationship as a Trusted Partner
and Sponsor of The Dr. Oz Show, is making it easier for our
Associates to introduce USANA to new customers in each of our
regions. Finally, investments in our personalization initiative and IT
infrastructure are designed to create the foundation for future growth
by making it easier, more exciting, and more enjoyable to partner with
USANA.
During the quarter, we also held our annual Asia Pacific convention in
Singapore, where thousands of our Associates gathered to celebrate their
success, meet with management and receive additional training. These
conventions also help generate momentum in our business, as we typically
see our sales force leave these events with renewed excitement and
motivation to grow their business.
Net earnings for the second quarter increased by 31.7% to $25.4 million
when compared with the prior-year period. This increase can be
attributed to leverage gained on higher net sales during the
quarter. Accordingly, we saw improvements in relative gross margins and
selling, general and administrative expense year-over-year. These
improvements were partially offset by higher Associate Incentives
expense. Although Associate Incentives expense increased 60 basis
points year-over-year to 43.7% of net sales, this line item decreased
250 basis points sequentially, largely as a result of our management of
market specific incentives and promotions. We continue to expect this
expense to be in the range of 44.0 to 44.5% of net sales for the
remainder of 2015.
Earnings per share for the quarter increased by 41.2% to $1.92, due to
higher net earnings and a lower number of diluted shares. Weighted
average diluted shares outstanding were 13.2 million at the end of the
second quarter of 2015, compared with 14.2 million for the prior-year
period. The reduced diluted share count contributed approximately $0.13
to earnings per share for the quarter. During the quarter, we did not
repurchase any shares of common stock. As of August 4, 2015, there was
$61.2 million remaining under the current share repurchase authorization.
Regional and Financial Results
Asia Pacific Region | Q2 2015 Net Sales of $168.7 million; 72.3% of
Consolidated Net Sales
Net sales in our Asia Pacific region increased by 35.4%
year-over-year. The number of active Associates in the region increased
by 53.2% year-over-year and 6.2% sequentially. This performance was the
result of double-digit growth in active Associates in each of our
Greater China, Southeast Asia Pacific, and North Asia regions. Net
sales in the region were negatively impacted by $5.1 million due to a
strengthening U.S. dollar.
Greater China. Net sales in Greater China increased 51.6%
year-over-year due to continued growth in Mainland China. Specifically,
local currency sales in Mainland China increased 83.6% year-over year,
while the number of active Associates nearly doubled. Net sales in the
region were minimally impacted by currency fluctuations.
Sales and customer growth in Mainland China continued to benefit from
momentum generated by the incentive that we offered during the fourth
quarter of 2014 and first quarter of 2015, as well as a smaller
promotion offered during the second quarter. During the quarter, we
continued to make progress on the remodel of our branch locations and
the construction of our new state-of-the-art production facility in
Beijing. This project is progressing on schedule and we continue to
anticipate that this facility will be operational in early 2016.
Southeast Asia Pacific. The 7.8% net sales increase in the
Southeast Asia Pacific region was driven by double-digit Associates
growth in each of the markets within this region. Net sales in the
region were negatively impacted by $4.5 million due to a strengthening
U.S. dollar.
North Asia. Net sales in North Asia increased 32.4%
year-over-year as a result of 44.4% Associate growth in the region. Net
sales in the region were negatively impacted by $814 thousand due to a
strengthening U.S. dollar. We are pleased with the momentum that we are
seeing in our Korean market.
Americas and Europe Region | Q2 2015 Net Sales of $64.5 million;
27.7% of Consolidated Net Sales
In the Americas and Europe region, net sales on a year-over-year basis
increased 1.4%, while the number of active Associates increased
8.5%. Sales were negatively impacted by $4.6 million due to a
strengthening U.S. dollar. We generated double-digit sales growth on a
constant currency basis in most markets within the region. In
particular, Canada and Mexico generated local currency sales growth of
22.2% and 20.6% respectively. The number of active Associates increased
12.0% in Canada and 20.0% in Mexico.
Balance Sheet
We ended the second quarter with $150.9 million in cash and cash
equivalents, zero debt, and $132.0 million in net working capital.
Although inventory increased 19.4% since year-end 2014, inventory turns
were in line with historical levels and indicative of an increased
demand for our product.
Quarterly Income Statement Discussion
Gross margins improved 130 basis points year-over-year, due in
large part to changes in our market sales mix, leverage gained on higher
net sales, and from price increases introduced during the first half of
the year. These improvements were partially offset by the negative
impact of a strengthening U.S. dollar.
Associate incentives expense for the quarter increased 60 basis
points year-over-year to 43.7% of net sales. As noted previously,
the relative increase in Associate Incentives expense was due largely to
higher spending on market specific incentive programs. Throughout 2015,
market-specific incentives and promotions will continue to be offered,
but on a smaller scale than the incentive offered earlier in the
year. These incentives will be consistent with our primary goal of
generating long-term customer growth as we seek to improve the overall
health and nutrition of individuals and families around the world.
Selling, general and administrative expense was 22.5% of net sales, a
decrease of 50 basis points compared to the prior year period. This
relative decrease was due primarily to leverage gained on higher
sales. This benefit was partially offset by the change in timing of
costs associated with our annual Asia Pacific Convention, which was held
in the second quarter of this year compared to the first quarter of last
year. Notably, fluctuations in currency exchange rates negatively
impacted relative SG&A by 30 basis points, on a comparative basis. On
an absolute basis, SG&A increased due to expenses related to our
business in China, along with investments in infrastructure, brand
recognition, and product innovation.
Outlook
During the third quarter, we are looking forward to hosting our annual
International Convention in Salt Lake City, Utah. We are once again
expecting record attendance as Associates from around the world come
together to celebrate and receive additional training. This event
continues to be an excellent platform for us to make exciting
announcements and to ensure that the vision and goals of the Company are
consistent with those of our independent sales force. We expect another
amazing event this year, which will be held August 19th through
the 22nd.
Additionally, we continue to look forward to opening Indonesia later
this year, which will be our 20th market. We have made excellent
progress since the announcement of our plans to enter this market and
continue to be excited and optimistic about the potential of our
business there.
Given our better than expected results in the first half of the year,
and the momentum we are seeing in our world-wide business, we expect
2015 to be another record year for USANA. In our earnings release
today, we provided the following updated consolidated net sales and
earnings per share outlook for 2015:
-
Consolidated net sales between $900 million and $920 million, versus
previous outlook of between $870 million and $890 million
-
Earnings per share between $6.90 and $7.20, versus previous outlook of
between $6.45 and $6.75
For the full-year 2015, we expect that Earnings from Operations will be
around 15.5% of net sales at the high-end of our net sales range. Our
outlook anticipates:
-
Associate Incentives expense of 44.0% to 44.5% of net sales for the
remainder of 2015;
-
Planned capital spending of approximately $45 million for our new
facility in China, branch upgrades, and investments in our
personalization initiative and information technology infrastructure;
-
An effective tax rate of approximately 34% for the full-year;
-
Continued headwinds from a strengthening U.S. dollar; and
-
A diluted share count of approximately 13 million shares.
As we continue to execute our current strategy, we will continue to
manage expenses and maximize efficiencies to capitalize on the leverage
opportunity presented by higher sales. Our primary goal remains the
growth of our customer base, which furthers the Company’s vision of
improving the overall health and nutrition of individuals and families
around the world. We look forward to delivering another record year for
USANA and all of its stakeholders.
Kevin Guest
President
Paul Jones
Chief Financial Officer
Forward-Looking Statements
This document contains forward-looking statements regarding future
events or the future financial performance of our company. Those
statements involve risks and uncertainties that could cause actual
results to differ perhaps materially from results projected in such
forward-looking statements. Examples of these statements include those
regarding our strategies and outlook for 2015. We caution you that
these statements should be considered in conjunction with disclosures,
including specific risk factors and financial data contained in our most
recent filings with the SEC.
Investor Relations Contact
Patrique Richards
801-954-7961
Investor.relations@us.usana.com
|
Media Contact
Dan Macuga
801-954-7280
Public Relations
|
7
Exhibit 99.3
USANA
Board of Directors Appoints Dave Wentz and Kevin Guest as Co-Chief
Executive Officers
SALT LAKE CITY--(BUSINESS WIRE)--August 4, 2015--USANA Health Sciences,
Inc. (NYSE: USNA) today announced that the Board of Directors has
appointed Dave Wentz and Kevin Guest as Co-Chief Executive Officers of
the Company, effective immediately. Mr. Wentz will oversee USANA’s
global operations, while Mr. Guest will lead USANA’s worldwide field
development and sales efforts. Both Mr. Guest and Mr. Wentz will report
directly to the Board of Directors.
Dr. Myron Wentz, USANA’s founder and Chairman of the Board, commented,
“Kevin has been with USANA for over 20 years, most recently as
President, and has played a key role in leading USANA to new heights in
sales and financial performance. Dave has also been with USANA for over
20 years and has served in executive positions for much of that time,
most recently as Chief Executive Officer. As USANA approaches the $1
billion revenue milestone, the Board is preparing for the next chapter
of growth. With USANA’s expanding global presence, and the demands on
the chief executive position, the Board determined that a division of
responsibilities within the CEO role would maximize USANA’s potential.”
Dave Wentz commented, “Kevin and I have worked as a team both formally
and informally for more than 20 years, and he has demonstrated his
leadership skills as President of our company. It is exciting to be able
to recognize Kevin for his contributions and have him join me as Co-CEO.
I look forward to sharing with him the growing CEO responsibilities as
USANA capitalizes on its many growth and expansion opportunities.”
Kevin Guest commented, “I am honored by the recognition from the Board
of Directors and Dave. Dave and I have worked side by side to achieve
many goals over the years, and I look forward to working with Dave and
the rest of our team as we take USANA to the next stage of growth.”
USANA also reported today that Paul Jones, Chief Financial Officer, has
been appointed Chief Leadership Development Officer, where he will be
responsible for the key role of overseeing USANA’s global executive
development and succession planning program. Mr. Jones will continue his
CFO responsibilities while the Company initiates a search for a new
Chief Financial Officer.
About USANA
USANA develops and manufactures high-quality nutritional supplements,
healthy foods and personal care products that are sold directly to
Associates and Preferred Customers throughout the United States, Canada,
Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea,
Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the
United Kingdom, Thailand, France, Belgium and Colombia. More information
on USANA can be found at http://www.usanahealthsciences.com.
Safe Harbor
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Our actual results could differ materially from
those projected in these forward-looking statements, which involve a
number of risks and uncertainties, including global economic conditions
generally, reliance upon our network of independent Associates, the
governmental regulation of our products, manufacturing and marketing
risks, adverse publicity risks, and risks associated with our
international expansion. The contents of this release should be
considered in conjunction with the risk factors, warnings, and
cautionary statements that are contained in our most recent filings with
the Securities and Exchange Commission.
CONTACT:
USANA Health Sciences, Inc.
Investors contact:
Patrique
Richards, 801-954-7961
Investor Relations
investor.relations@us.usana.com
or
Media
contact:
Dan Macuga, 801-954-7280
Public Relations
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
USANA Health Sciences (NYSE:USNA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024